Applicability of different antibodies for immunohistochemical localizationof CFTR in sweat glands from healthy controls and from patients with cystic fibrosis

Citation
A. Claass et al., Applicability of different antibodies for immunohistochemical localizationof CFTR in sweat glands from healthy controls and from patients with cystic fibrosis, J HIST CYTO, 48(6), 2000, pp. 831-837
Citations number
26
Categorie Soggetti
Medical Research Diagnosis & Treatment
Journal title
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
ISSN journal
00221554 → ACNP
Volume
48
Issue
6
Year of publication
2000
Pages
831 - 837
Database
ISI
SICI code
0022-1554(200006)48:6<831:AODAFI>2.0.ZU;2-V
Abstract
The hereditary disease cystic fibrosis (CF) is caused by mutations in the c ystic fibrosis transmembrane conductance regulator (CFTR) gene. Understandi ng of the consequences of CFTR gene mutations is derived chiefly from in vi tro studies on heterologous cell cultures and on cells hyperexpressing CFTR . Data from ex vivo studies on human tissue are scarce and contradictory, a fact which is in part explained by secondary tissue destruction in most af fected organs. The purpose of this study was to establish conditions under which wild-type and mutated CFTR can be studied in affected human tissue. S weat glands carry the basic defect underlying CF and are not affected by ti ssue destruction and inflammation. Therefore, we used this tissue to test a panel of eight different CFTR antibodies under various fixation techniques . The antibodies were tested on skin biopsy sections from healthy controls, from CF patients homozygous for the most common mutation, Delta F508, and from patients carrying two nonsense mutations. Of the eight CFTR antibodies , only three-M3A7, MATG 1104, and cc24-met the criteria necessary for immun olocalization of CFTR in sweat glands. The labeling pattern in the CF sweat glands was consistent with the postulated processing defect: of Delta F508 CFTR. The antibodies exhibited different sensitivities for detecting Delta F508 CFTR.